Valuation : Milestone Pharmaceuticals Inc.

Market Cap 166M 143M 134M 122M 231M 15.86B 232M 1.59B 614M 8B 624M 611M 26.5B P/E 2026 *
-1.4x
P/E 2027 * -1.41x
Enterprise Value 166M 143M 134M 122M 231M 15.86B 232M 1.59B 614M 8B 624M 611M 26.5B EV / Sales 2026 *
43.4x
EV / Sales 2027 * 7.51x
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.72%
1 week+9.26%
Current month+6.31%
1 month+1.72%
3 months-15.71%
6 months-31.40%
Current year-41.58%
1 week 1.02
Extreme 1.02
1.19
1 month 1.01
Extreme 1.01
1.29
Current year 1
Extreme 1
2.34
1 year 1
Extreme 1
3.06
3 years 0.63
Extreme 0.6254
3.52
5 years 0.63
Extreme 0.6254
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 07/03/2017
Director of Finance/CFO 53 09/09/2019
Compliance Officer 48 10/02/2026
Director TitleAgeSince
Director/Board Member 59 01/07/2017
Director/Board Member 60 01/04/2019
Director/Board Member 67 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Director

77,000 0.0618%
02/02/26 Free

Chief Operating Officer

204,000 0.2395%
02/02/26 Free

Chief Executive Officer

679,000 0.7972%
Change 5-day change 1-year change 3-year change Capi.($)
+1.72%+9.26%-30.18%-58.60% 166M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.14%+2.55%+49.41%+93.31% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.49%+1.73%+59.01%+11.60% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
+1.16%+2.06%+37.68%-16.92% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%-1.59%+13.19%+543.56% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.66%+1.97%+50.74%+171.73% 28.85B
Weighted average by Cap. +1.08%+0.72%+56.52%+157.52%

Financials

2026 *2027 *
Net sales 3.83M 3.29M 3.08M 2.82M 5.32M 365M 5.34M 36.5M 14.14M 184M 14.37M 14.06M 610M 22.14M 19M 17.83M 16.29M 30.74M 2.11B 30.89M 211M 81.79M 1.07B 83.12M 81.32M 3.53B
Net income -117M -100M -94.05M -85.9M -162M -11.13B -163M -1.11B -431M -5.62B -438M -429M -18.61B -131M -112M -105M -96.28M -182M -12.48B -183M -1.25B -483M -6.3B -491M -481M -20.86B
Net Debt - -
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change
26/08/26 $1.180 +1.72%
25/08/26 $1.160 +11.54%
24/08/26 $1.040 -1.42%
21/08/26 $1.055 +2.43%
20/08/26 $1.030 -4.63%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.180USD
Average target price
5.857USD
Spread / Average Target
+396.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIST Stock